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Abstract
Background: Despite the widespread induction of miR-146a during the innate immune response little is known 
regarding its biogenesis, function and mechanism. We have therefore examined the role of miR-146a during the 
interleukin (IL)-1β-stimulated IL-6 and IL-8 release and proliferation in primary human airway smooth muscle (HASM) 
cells.
Methods: HASM cells were isolated from human lung re-section, cultured to a maximum of 3 - 6 passages and then 
exposed to IL-1β. miR-146a expression were determined by qRT-PCR, IL-6 and IL-8 release by ELISA and proliferation 
using bromodeoxyuridine incorporation. The role of NF-κB and the MAP kinase pathways was assessed using 
pharmacological inhibitors of IKK2 (TPCA-1), JNK (SP600125), p38 MAP kinase (SB203580) and MEK-1/2 (PD98059). miR-
146a function was determined following transfection of HASM with inhibitors and mimics using Amaxa 
electroporation.
Results: IL-1β induced a time-dependent and prolonged 100-fold induction in miR-146a expression, which correlated 
with release of IL-6 and IL-8. Exposure to IL-1β had no effect upon HASM proliferation. Pharmacological studies showed 
that expression of primary miR-146a was regulated at the transcriptional levels by NF-κB whilst post-transcriptional 
processing to mature miR-146a was regulated by MEK-1/2 and JNK-1/2. Functional studies indicated that IL-1β-induced 
miR-146a expression does not negatively regulate IL-6 and IL-8 release or basal proliferation. However, inhibition of IL-
1β-induced IL-6 and IL-8 release was observed at the super-maximal intracellular miR-146a levels obtained by 
transfection with miR-146a mimics and indicates that studies using miRNA mimics can produce false positive results. 
Mechanistic studies showed that in the presence of super-maximal levels, the action of miR-146a mimics was mediated 
at a step following IL-6 and IL-8 mRNA transcription and not through down-regulation of IL-1 receptor associated 
kinase 1 (IRAK-1) and TNF receptor-associated factor 6 (TRAF6) protein expression, two predicted miR-146a targets 
involved in IL-1β signalling.
Conclusions: We have shown that IL-1β-induced miR-146a expression in HASM and that this was regulated at the 
transcriptional level by NF-κB and at the post-transcriptional level by the MEK-1/2 and JNK-1/2. Unlike previous reports, 
studies using miRNA inhibitors showed that miR-146a expression did not regulate IL-6 and IL-8 release or proliferation 
and suggest miR-146a function and mechanism is cell-type dependent.
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Introduction
Human airway smooth muscle (HASM) cells regulate
both the tone and diameter of the respiratory airways.
Inappropriate contraction of HASM in response to envi-
ronmental stimuli is responsible for the reversible air-
ways contraction that is associated with asthma, a
chronic disease that affects approximately 10% of chil-
dren and 5% of adults in Western countries [1,2]. In addi-
tion to their role in constriction, HASM cells are also
thought to contribute towards the chronic inflammation
and airway re-modelling that is characteristic of asthma
[3,4]. Thus, HASM cells have been shown to release a
h o s t  o f  i n f l a m m a t o r y  m e d i a t o r s  s u c h  a s  I L - 6 ,  I L - 8 ,
eotaxin, matrix metalloproteinase-12 and prostaglandin
E2 and to undergo proliferation in response to activation
via the Toll like receptor (TLR)/interleukin (IL)-1 recep-
tor family [5-13].
Members of the TLR/IL-1 receptor family possess a
common intracellular domain and can be subdivided into
the TLR family that comprises at least 11 members and
the IL-1R family that has 10 members [14,15]. The TLRs
recognise conserved molecules derived from bacteria,
fungi and viruses and contribute towards the innate
immune response whilst the IL-1Rs are activated by the
pro-inflammatory cytokines, IL-1α, IL-1β, IL-18 and IL-
33 [15]. Agonism of these receptors leads to the activa-
tion of a common intracellular signalling pathway. The
initial step involves association with the adaptor protein
myeloid differentiation primary-response gene 88
(MyD88), which recruits IL-1R associated kinase 1
(IRAK-1) and TNF receptor-associated factor 6 (TRAF6).
In HASM cells, these receptors activate a variety of intra-
cellular signalling pathways and pro-inflammatory tran-
scription factors. One of the most important is NF-κB,
which under basal conditions is localized within the cyto-
plasm bound to IκBα. Degradation of IκBα following
phosphorylation by I-κB kinase-2 (IKK-2) results in the
nuclear translocation of activated NF-κB, DNA binding
and subsequent transcription of multiple inflammatory
mediators [6,16,17]. Alternative pathways that are known
to be activated in HASM cells include the mitogen acti-
vated kinase cascades that terminate at ERK-1/2, JNK-1/2
and p38 MAP kinase [6,10,17-21].
miRNA-mediated RNA interference has been identi-
fied as a novel mechanism that regulates gene expression
at the translational level [22,23]. These short RNA
sequences of 20-23 nucleotides are produced by the pro-
cessing of full length mRNA-like transcripts known as
primary miRNAs [24,25]. These larger primary miRNA
transcripts undergo enzymatic cleavage by the RNAse III
enzyme Drosha to produce ~70 nt precursor miRNAs.
These are then transported to the cytoplasm where they
are further processed by another RNAse III enzyme,
DICER, to produce ~21-23 double stranded RNA. One
strand, the mature miRNA, is then loaded into the RNA-
induced silencing complex (RISC) where it is believed to
either repress mRNA translation or reduce mRNA stabil-
ity following imperfect binding between the miRNA and
the miRNA-recognition elements (MRE) within the 3'
untranslated region (UTR) of target genes. Specificity of
the miRNA is thought to be primarily mediated by the
'seed' region that is localised between residues 2-8 at the
5' end [26-28]. Interestingly, recent studies have identified
miRNA-mediated RNA interference as a potentially
novel mechanism that regulates the immune response
[29-31]. In particular, rapid increases in miR-146a and
miR-155 expression have been demonstrated in immune
cells following activation of members of the TLR/IL-1R
family [32-37]. Since these initial observations, miR-155
has been shown to regulate multiple responses associated
with the innate and acquired immune response including
LPS-induced release of inflammatory mediators from
monocytes, T cells and B cells [34,38,39], proliferation
and differentiation of myeloid and lymphoid cells [40-44]
and B cell antibody switching [45-47]. Significantly, these
studies indicate that the function and mechanism of miR-
155 is dependent upon the cell-type and stage of develop-
ment/differentiation.
In contrast to miR-155, much less is known regarding
the biological role of miRNA-146a. This is despite its
widespread induction in both immune and structural
cells, such as alveolar and airway epithelial cells, mono-
cytes/macrophages, fibroblasts and chondrocytes follow-
ing the initiation of the innate immune response [32,48-
54]. Studies into the mechanisms that regulate miR-146a
expression has demonstrated that the initial transcription
of primary miR-146a is mediated via activation of NF-κB
[32,48,49,55,56]. In contrast, nothing is known regarding
the mechanisms that regulate the processing of primary
miR-146a to produce the mature miR-146a. Interestingly,
recent studies have indicated that TGFβ-induced miR-21
production in human pulmonary artery smooth muscle is
primarily regulated at the level of Drosha, which pro-
cesses primary miR-21 to precursor miR-21, and is driven
by activation of the Smad signalling pathway [57]. Evi-
dence of the importance of post-transcriptional regula-
tion has also been provided from studies of the single-
strand RNA-binding protein KH-type splicing regulatory
protein (KSRP). This has been shown to serve as a com-
ponent of both Drosha and Dicer complexes and regu-
lates the biogenesis of a subset of miRNAs through
binding with high affinity to the terminal loop of the tar-
get miRNA precursors and promoting their maturation
[58]. In particular, KSRP has been shown to regulate the
maturation miR-155 and the subsequent down-regula-
tion of inflammatory mediators following LPS-stimula-
tion of bone marrow derived macrophages [39].Larner-Svensson et al. Respiratory Research 2010, 11:68
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Functional studies indicate that miR-146a negatively
regulates the release of inflammatory mediators,
although there are differing reports as to the precise
mechanism of action [32,48,49]. Taganov et al [32] have
suggested that miR-146a targets the down-regulation of
IRAK-1 and TRAF6, which are located in the TLR/IL-1R
signalling pathway. This hypothesis has been supported
by recent studies of miR-146a mediated down-regulation
of IFN-β release in vesicular stomatitis virus (VSV)-
infected mouse peritoneal macrophages [49]. In contrast,
our previous studies in IL-1β-stimulated human alveolar
A549 epithelial cells indicated that miR-146a attenuated
IL-8 and RANTES release at a step following their tran-
scription and not through the targeting of IRAK1 and
TRAF6 [48].
To further characterise the function and mechanism of
action of miR-146a, we have examined the IL-1β-induced
response in primary HASM cells. In contrast to the rapid
induction in miR-146a expression previously described
[32,48,49], we observed a slow-developing and prolonged
induction of miR-146a expression. We have confirmed
that NF-κB regulates miR-146a transcription and demon-
strate for the first time, that the post-transcriptional pro-
cessing of primary miR-146a to mature miR-146a is
regulated by MEK-1/2 and JNK-1/2. Significantly, func-
tional studies indicated that IL-1β-induced miR-146a
expression is not central to the negative regulation of IL-6
and IL-8 release or basal proliferation in HASM cells
under physiological conditions. However, we demon-
strated that transfection with super-maximal levels of
miR-146a could inhibit IL-1β-induced IL-6 and IL-8
release and under these conditions, we confirmed our
previous observation that the action of miR-146a was
mediated at a step following the transcription of IL-6 and
IL-8 and not through down-regulation of IRAK-1 and
TRAF6.
Methods
Ethics Statement
This study received written approval from the National
Heart and Lung Institute and Royal Brompton Hospital
NHS Trust Ethics Committee and all subjects gave
informed written consent to participate in the study.
Isolation and culture of human airway smooth muscle cells
HASM was obtained from lobar or main bronchus of
patients undergoing lung resection for carcinoma of the
bronchus. The smooth muscle was dissected out under
sterile conditions and placed in culture. Cells were main-
tained in Dulbecco's modified Eagle's medium (DMEM)
containing 10% foetal calf serum (FCS) supplemented
with sodium pyruvate (1 mM), L-glutamine (2 mM), pen-
icillin (100 U/ml) streptomycin (100 μg/ml) and amphot-
ericin B (1.5 μg/ml) in a humidified atmosphere at 37°C in
air/CO2. HASM cells at passages 3-6 from 20 different
donors were used in the studies described.
Cell stimulation
HASM cells were plated onto 6-well plates for assessment
of cytokine release and RNA extraction. Prior to experi-
ments, confluent cells were growth-arrested by FCS
deprivation for 24 h in DMEM supplemented with
sodium pyruvate (1 mM), L-glutamine (2 mM), nonessen-
tial amino acids (1:100), penicillin (100 U/ml)/streptomy-
cin (100 μg/ml), amphotericin B (1.5 μg/ml), and bovine
serum albumin (0.1%). Cells were stimulated in triplicate
in a fresh FCS-free medium with the indicated IL-1β con-
centration or with 1 ng/ml IL-1β for indicated times. To
examine the effect of the inhibitors of JNK (SP600125)
[54,55], IKK2 (TPCA-1) [56,57], p38 MAP kinase
(SB203580) [58,59] and MEK-1/2 (PD98059) [60,61] the
indicated concentration (in the range 0.1 to 10 μM) was
added 60 min prior to the addition of IL-1β (1 ng/ml). At
the indicated times, the levels of IL-6 and IL-8 were
d e t e r m i n e d  b y  D u o S e t  E L I S A  ( R & D  S y s t e m s )  a n d  t h e
remaining cells were extracted for RNA (using a miRVana
extraction kit, Ambion).
Measurement of cell number
After the supernatants were removed from the cells, 200
μl of MTT solution (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) was added and left to incu-
bate for 30 min or until sufficient colour developed. Cells
were washed and 200 μl of DMSO (Sigma-Aldrich) was
added to each well. The optical density (OD) was mea-
sured at 550 nm using a spectrophotometer plate reader
and expressed as a % of the control.
Measurement of cell proliferation
Cell proliferation was quantified using a DNA bromode-
oxyuridine (BrdU) incorporation assay (Roche Applied
Science, Burgess Hill, UK). The amount of incorporated
BrdU is a measure of the rate of DNA synthesis of the
cells and thus indirectly of cell proliferation. The cell pro-
liferation kit was used according to the manufacturer's
instructions. Briefly, HASM cells were seeded in DMEM
containing 10% FCS in 96-well cell culture plates at a den-
sity of 3,500 cells/well. At 30-50% confluence, the
medium was changed to required concentration of FCS
and cells were treated with/out IL-1β (1 ng/ml) for indi-
cated time. At 24 h prior to the end of the stimulation
period, BrdU labelling solution were added to each well at
a final concentration of 10 μM. At the end of the stimula-
tion period, cells were fixed (60 min) and then incubated
for 90 min at room temperature, with 1/100 dilution of
peroxidase labelled anti-BrdU antibody. The wells were
then washed three times, incubated for 5 mins at room
temperature with substrate solution and the lumines-Larner-Svensson et al. Respiratory Research 2010, 11:68
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cence was measured using a Fluorostar plate reader
(BMG, Offenburg, Germany).
Transfection with miR-146a mimics and inhibitors
HASM cells were transfected using Basic Nucleofector
kit for primary smooth muscle cells according to manu-
facturer's instructions using Amaxa Nucleofector II
device (program P-13) (Amaxa Biosystems, Cologne,
Germany). miR-146a mimics and controls were obtained
from Ambion/Applied Biosystems Ltd and locked nucleic
acid (LNA)-based miR-146a inhibitors and controls were
obtained from Exiqon Ltd. Transfected cells were plated
i n t o  6 - w e l l  p l a t e s  a n d  l e f t  t o  a d h e r e  o v e r n i g h t  b e f o r e
being serum starved for 6 h prior to stimulation with 1
ng/ml IL-1β. Supernatants were removed at 24 h and IL-
6, IL-8 and IFN- levels were determined by DuoSet
ELISA (R&D Systems). The remaining cells were
extracted for RNA (using a miRVana extraction kit,
Ambion) or tested for viability by MTT assay.
Measurement of miRNAs, primary miR-146a and mRNA 
expression
Total RNA was extracted using the mirVana™miRNA iso-
lation kit (Ambion Europe) according to the manufac-
turer's instructions. RNA was eluted in 50 μl RNase-free
water (Promega UK, Southampton, UK) and stored at -
70°C. RNA content and purity was measured using a
BioTek PowerWave XS (SSi Robotics, Tustin, CA, U.S.A.)
spectrophotometer. miRNA expression profiling was car-
ried out on total RNA extracts by two-step TaqMan®
reverse transcription polymerase chain reaction protocol
(RT-PCR) as previously described [36]. mRNA expres-
sion levels of IRAK-1, TRAF6, IL-6 and IL-8 was deter-
mined using semi-quantitative two-step RT-PCR as
previously described [62] using Assay on Demand
primer/probe sets obtained from Applied Biosystems,
UK. Primary miR-146a expression was determined using
RT-PCR and Sybr green detection using the following
primers: forward: CAAAGGCTTTGAAGGC-
CTCTCTA; reverse: ATGGCACCCAGCTGACCAT. All
miRNA, primary miRNA and mRNA samples were nor-
malised against 18 S (Applied Biosystems, Catalogue
Number 4310893E). The separate well, 2-(ΔΔCt) method
[63] was used to determine relative-quantitative levels of
individual mRNAs, miRNAs and primary miR-146a, and
these were expressed as the fold-difference to the relevant
controls.
Western Blotting
Proteins were extracted from HASM cells as previously
described [59], separated upon 10% SDS-PAGE (Invitro-
gen) and transferred to nitrocellulose (Amersham Ltd).
Protein (20 μg) were detected by Western blotting using a
rabbit anti-TRAF6 antibody (H-274) [60], rabbit anti-
IRAK-1 antibody (H-273)[61] obtained from Santa Cruz
Biotechnology. All primary antibodies were used a con-
centration of 1:200 or 1:400 and were incubated over-
night. Labelling of the first antibody was detected using
relevant secondary antibodies conjugated to HRP (Dako
Ltd) and detected using ECL reagents (Amersham Ltd.,
UK).
Data and statistical analysis
The results presented are the mean ± SEM of at least
three independent experiments. Statistical analysis was
performed using the Mann-Whitney U-test which
assumed non-parametric distribution. P values of < 0.05
were considered significant and are indicated with aster-
isks.
Results
IL-1β-induced a time- and concentration-dependent 
increase in miR-146a expression
As previous investigations have implicated miR-146a and
miR-155 in the regulation of TLR/IL-1R-induced
response, we measured their expression following expo-
sure to IL-1β (1 ng/ml) in HASM cells. Although there
was variability between human donors, IL-1β caused a 23
± 8-fold increase in miR-146a expression levels at 6 h,
which continued to rise to 81 ± 29 and 131 ± 33-fold at 24
h and 72 h, respectively (Figure 1A). In contrast, we
observed no significant changes in miR-146a* (reverse
strand to the mature miR-146a strand), miR-146b or miR-
155 levels (Figure 1A). Increasing IL-1β concentration
showed that miR-146a expression was maximal at
approximately 0.1 ng/ml (Figure 1B).
In subsequent studies, we measured the levels of the
primary miR-146a in response to IL-1β. In contrast to
mature miR-146a, primary miR-146a expression was
increased by only 2-4 fold and maximal release was
observed at 6 h, suggesting that the increase in mature
miR-146a expression at 24 h and 72 h was due to regula-
tion at the post-transcriptional level. Maximal expression
of primary miR-146a production was observed at 0.1 ng/
ml IL-1β (Figure 2).
IL-1β-induced time- and concentration-dependent IL-6 and 
IL-8 release
We subsequently assessed the effect of IL-1β upon the
release of the pro-inflammatory mediators, IL-6 and IL-8
in HASM cells. IL-1β-induced a time- and concentration-
dependent release of IL-6 and IL-8 (Figure 3). However,
although we observed a significant elevation in both
cytokines at 6 h, the IL-8 response reached a plateau at
approximately 24 h, whilst IL-6 continued to increase
throughout the 72 h period (Figure 3A). Examination of
the effect of increasing IL-1β upon IL-6 and IL-8 release
at 24 h showed similar concentration response curvesLarner-Svensson et al. Respiratory Research 2010, 11:68
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with an EC50 value of ~0.03 ng/ml and maximal release at
1 ng/ml (Figure 3B). Given that we wanted to examine the
role of miR-146a during IL-6 and IL-8 release subsequent
studies were performed at 1 ng/ml IL-1β.
IL-1β-induced miR-146a expression is regulated at the 
transcriptional and post-transcriptional level
In previous studies, we and others have demonstrated
that IL-1β-induced activation of IKK2/NF-κB and the
MAP kinases, ERK-1/2, JNK-1/2 and p38 MAP kinase in
HASM cells and that these are inhibited in the presence
of the selective pharmacological inhibitors of TPCA-1
(IKK2), PD098059 (MEK-1/2), SP600125 (JNK-1/2) and
SB203580 (p38 MAP kinase), respectively [6,10,17-21].
We therefore used the biological active concentrations of
these inhibitors to examine the role of the NF-κB and
MAP kinases pathways during miR-146a expression.
Following 60 min pre-treatment with inhibitors, HASM
cells were stimulated with IL-1β and the generation of IL-
6 (Figure 4), IL-8 (Figure 4), miR-146a (Figure 5) and pri-
mary miR-146a (Figure 5) were determined at 24 h. Expo-
sure to TPCA-1 completely inhibited production of IL-6,
IL-8 and miR-146a expression at 10 μM. This did not
appear to have resulted from cell death since parallel
studies showed a small (~15%) but non-significant reduc-
t i o n  i n  c e l l  v i a b i l i t y  ( A d d i t i o n a l  F i l e  1 ) .  T h e  M E K - 1 / 2
inhibitor (10 μM) also attenuated IL-6, IL-8 and miR-
146a production although this was less pronounced than
Figure 1 IL-1β-induced a time- and concentration-dependent in-
crease in miR-146a expression. HASM cells were exposed to either 
vehicle control or 1 ng/ml IL-1β for the indicated time or to the indicat-
ed IL-1β concentration for 24 h. The time dependent expression of 
miR-146a, miR-146a*, miR-146b and miR-155 (A) or the concentration 
dependent miR-146a expression (B) was determined by qRT-PCR. The 
results are expressed as the mean ± SEM of four independent experi-
ments where * p < 0.05 versus time-matched controls.
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Figure 2 IL-1β-induced a time- and concentration-dependent in-
crease in primary miR-146a expression. HASM cells were exposed 
to either vehicle control or 1 ng/ml IL-1β for the indicated time or to 
the indicated IL-1β concentration for 24 h. The time- (A) and concen-
tration- (B) dependent expression of primary miR-146a was deter-
mined by qRT-PCR. The results are expressed as the mean ± SEM of 
four independent experiments where * p < 0.05 versus time-matched 
controls.
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TPCA-1 inhibition and resulted in reductions of ~42%,
41% and 52%, respectively. In contrast, inhibition of the
JNK-1/2 (SP600125) and p38 MAP kinase (SB203580)
had differential actions upon cytokine and miR-146a pro-
duction. Thus, JNK-1/2 inhibition had no effect upon IL-
6 and IL-8 release but inhibited miR-146a expression,
whilst blocking p38 MAP kinase inhibited IL-8 but not
IL-6 or miR-146a production. In order to confirm these
pharmacological studies, we also attempted to use
siRNA-mediated knockdown to examine the role of IKK2
and the MAP kinases. Unfortunately, this was not possi-
ble since transfection with control siRNA blocked IL-1β-
induced miR-146a expression (data not shown), possibly
through competition between siRNA and primary/pre-
cursor miR-146a in the miRNA processing pathway.
Overall, pharmacological studies indicate that IL-1β-
induced miR-146a expression is regulated via an IKK2-,
MEK-1/2- and JNK-1/2-dependent pathway. Signifi-
cantly, the effect of the JNK inhibitor indicated that IL-
1β-induced miR-146a expression is not central to the reg-
ulation of IL-6 and IL-8 release. Thus, JNK inhibitor con-
centrations that attenuated mature miR-146a expression
had no significant action upon IL-6 and IL-8 release.
To ascertain whether the actions of IKK2, MEK-1/2 and
JNK-1/2 upon miR-146a expression were mediated at the
transcriptional or post-transcriptional level, we also
examined the action of these inhibitors upon expression
of primary miR-146a (Figure 5). These investigations
showed that primary miR-146a levels were attenuated by
an inhibitor of IKK2 but not MEK-1/2 or JNK-1/2. Signif-
icantly, since these inhibitors were shown to have no
effect upon cell viability (Additional File 1), this implied
that miR-146a expression was regulated at the transcrip-
tional level through activation of IKK2 (i.e. through NF-
κB activity), whilst the post-transcriptional processing of
primary miR-146a to produce mature miR-146a is regu-
lated via a MEK-1/2- and JNK-1/2-dependent mecha-
nism.
Figure 4 Effect of inhibitors of IKK2 and MAP kinases upon IL-1β-
induced IL-6 and IL-8 release. HASM cells were pre-treated for 60 min 
with the indicated concentrations of the inhibitors of IKK-2 (TPCA-1), 
MEK-1/2 (PD098059), JNK-1/2 (SP600125) and p38 MAP kinase 
(SB203580). Following exposure to vehicle control or IL-1β (1 ng/ml) 
for 24 h the release of IL-6 and IL-8 was determined by ELISA. Results 
are the mean ± SEM of 3 independent experiments where * p < 0.05 
versus IL-1β-stimulated cells.
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Figure 5 Effect of inhibitors of IKK2 and MAP kinases upon IL-1β-
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were pre-treated for 60 min with the indicated concentrations of the 
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146a was determined by qRT-PCR. Results are the mean ± SEM of 3 in-
dependent experiments where * p < 0.05 versus IL-1β-stimulated cells.
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IL-1β-induced miR-146a expression does not negatively 
regulate IL-6 and IL-8 release
In contrast to previous studies in alveolar epithelial cells
and monocytes/macrophages, the studies using the JNK
inhibitor suggested that increased miR-146a expression
did not negatively regulate the release of inflammatory
mediators. To clarify the role of miR-146a in the inflam-
matory response of HASM cells, we examined the action
of miR-146a inhibitors and mimics on IL-1β-induced IL-
6 and IL-8 release. In support of the observations using
the JNK inhibitor, transfection using Amaxa electropora-
tion showed that miR-146a inhibitors, at concentrations
up to 100 nM, had no significant effect on IL-8 release
(Figure 6A). In the case of IL-6, although the miR-146a
inhibitor (100 nM) attenuated cytokine release this
appeared to be a non-specific effect since this was also
seen in the presence of the miRNA control inhibitor (Fig-
ure 6A). In contrast, the miR-146a mimic (100 nM) pro-
duced 23% and 62% reduction in IL-1β-induced IL-6 and
IL-8 release, respectively (Figure 6B).
To confirm efficient transfection, the levels of miR-146a
in cells electroporated with miR-146a mimics were mea-
sured by TaqMan and showed efficient transfection (Fig-
ure 7 - see below). Under the same condition, we have
also demonstrated complete abolition of miR-146a
expression in the presence of miR-146a inhibitor (data
not shown). To provide additional evidence of transfec-
tion, we undertook parallel studies that examined the
effect of an siRNA (100 nM) targeted to IL-6 and showed
a 50% reduction in IL-6 release but no significant action
upon IL-8 generation following IL-1β-stimulation (Figure
6C).
To understand the reason that miR-146a mimics
reduced IL-1β-induced IL-6 and IL-8 release (Figure 6B),
we measured the levels of miR-146a in HASM cells.
These studies were performed following transfection
with 100 nM miR-146a mimic since this concentration
inhibited IL-1β-induced IL-6 and IL-8 release (Figure 6B).
Significantly, cellular miR-146a levels were increased by
3000-fold following electroporation in the presence of
miR-146a mimic, compared with the 20-50-fold increase
in response to IL-1β exposure (Figure 7). This observa-
tion would suggest that although miR-146a mimics can
attenuate IL-6 and IL-8 release, this is a false positive
observation that is likely to be due to supra-maximal lev-
els miR-146a levels which cannot be attained following
exposure to IL-1β. Overall, the studies using JNK-1/2 and
miR-146a inhibitors indicate that IL-1β-induced miR-
146a expression is not central to the negative feedback
regulation of IL-6 and IL-8 release.
Figure 6 Effect of miR-146a inhibitors and mimics upon IL-1β-in-
duced IL-6 and IL-8 release. HASM cells were electroporated in the 
presence of buffer (A-C), control inhibitor or miR-146a inhibitor (A), 
control mimic or miR-146a mimic (B) and control siRNA or an siRNA tar-
geted at IL-6 (C). Cells were then exposed to vehicle control or 1 ng/ml 
IL-1β and the release of IL-6 and IL-8 was measured by ELISA at 24 h. 
The results are mean ± SEM of three independent experiments where 
* p < 0.05 versus IL-1β-stimulated cells.
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IL-1β-induced miR-146a expression does not regulate 
proliferation
Since previous studies have indicated that changes in
miR-146a expression might regulate proliferation in a
range of cancer cell lines [62,63] we therefore decided to
investigate whether IL-1β-induced miR-146a expression
might regulate HASM proliferation. Under the fetal calf
serum (FCS)-free conditions used in these studies, IL-1β
at concentrations up to 10 ng/ml did not induce a signifi-
cant increase in HASM proliferation (Figure 8A) or cell
number (Figure 8B) at 48 h, 72 h and 96 h. In contrast,
FCS induced a concentration-dependent increase in pro-
liferation at 48 h and 72 h (Figure 8A) which was reflected
in an increase in cell number at 72 h and 96 h (Figure 8B).
Given that IL-1β failed to impact upon proliferation and
cell number, this suggested that miR-146a does not regu-
late these responses in HASM. To provide additional evi-
dence to support this conclusion, we examined the role of
miR-146a inhibitors and mimics at 48 h upon basal prolif-
eration i.e. in the absence of FCS. From Figure 8C, it can
be seen that neither miR-146a inhibitors or mimics had
an effect upon basal proliferation or cell number in IL-1β-
stimulated HASM cells.
Mechanism of inhibition of IL-6 and IL-8 release by miR-
146a mimics
Previous studies have indicated that inhibition of inflam-
matory mediator release by miR-146a is mediated
through the down-regulation of IRAK-1 and TRAF6,
which have multiple, predicted, miR-146a binding sites
and form part of the common intracellular pathway that
is activated via TLR/IL-1Rs [32,49]. Therefore, studies
were undertaken to determine whether increased miR-
146a levels following transfection with miR-146a mimics
impacted on IRAK-1 and TRAF6 expression. Examina-
tion of IRAK-1 and TRAF6 mRNA expression showed a
significant reduction of 51% and 55% at 24 h following IL-
1β stimulation, respectively (Figure 9A). However, this
reduction in mRNA expression was not reflected by a
concomitant decrease in IRAK-1 and TRAF6 protein
expression (Figure 9B). Exposure of non-stimulated cells
to the miR-146a mimic resulted in a 84% and 62% reduc-
tion in the IRAK-1 and TRAF6 mRNA expression and
further reductions in IRAK-1 and TRAF6 expression in
IL-1β-stimulated HASM cells from 51% to 15% (IRAK-1)
and 55% to 37% (TRAF6) (Figure 9A). Significantly, these
reductions in IRAK-1 and TRAF6 mRNA levels were also
reflected by a decrease in IRAK-1 and TRAF6 protein
expression in both control and IL-1β-stimulated HASM
cells in the presence of miR-146a mimic (Figure 9B). The
control mimic had no effect upon IRAK-1 and TRAK6
Figure 8 Effect of miR-146a inhibitors and mimics upon IL-1β-in-
duced proliferation and cell number. HASM cells were exposed to 
either vehicle control, the indicated FCS concentration or the indicated 
concentration of IL-1β for 48 h, 72 h or 96 h before measurement of 
proliferation (A) or cell number (B). In panel C, HASM cells were elec-
troporated in the presence of buffer, control inhibitor or miR-146a in-
hibitor, control mimic or miR-146a mimic. Cells were then exposed to 
vehicle control or 1 ng/ml IL-1β and proliferation and cell number was 
measured at 48 h. These results are mean ± SEM of three independent 
experiments.
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mRNA expression (Figure 9A) but appeared to cause a
non-selective reduction in IRAK-1 and TRAF6 protein
expression in IL-1β treated but not control cells (Figure
9B). The reason for this reduction is unknown although
we speculate that mimic controls might interact with
pathways that regulated IRAK1 and TRAF6 translation
but not transcription in activated cells.
Since the miR-146a mimics reduced both IRAK-1 and
TRAF6 mRNA and protein expression, we examined
whether this could account for the inhibition of IL-6 and
IL-8 release. To this end, we determined the effect of the
miR-146a mimics on IL-1β induced IL-6 and IL-8 mRNA
production. Exposure of HASM cells to IL-1β produced
1100- and 5700-fold increases in the levels of IL-6 and IL-
8 mRNA, respectively (Figure 10A). Despite the fact that
the miR-146a mimics had been previously shown to
attenuate extracellular IL-6 and IL-8 release, we observed
no significant inhibition of IL-6 or IL-8 mRNA expres-
sion (Figure 10B). These mechanistic studies indicate that
although over-expression of miR-146a following transfec-
tion with miRNA mimics can partially down-regulate
IRAK-1 and TRAF6 protein expression, this is not
responsible for inhibition in IL-6 and IL-8 release from
HASM. Instead, the action of the miR-146a mimics is
mediated at a post-transcriptional stage following IL-6
and IL-8 synthesis.
Discussion
Taganov at al [32] were the first to demonstrate increased
miR-146a expression following activation of the TLR/IL-
1R pathway. They also speculated that this might nega-
tively regulate the innate immune response through
down-regulation of IRAK-1 and TRAF6, two proteins
t h a t  a r e  i n v o l v e d  i n  T L R / I L - 1 R  s i g n a l l i n g  [ 3 2 ] .  I n  t h e
intervening period, the potential role of miR-146a as a
negative regulator of the immune response has been
highlighted by studies showing TLR/IL-1R-mediated
miR-146a expression in multiple cell types and that
changes in miR-146a expression is associated with
inflammatory diseases including rheumatoid arthritis,
osteoarthritis and systemic lupus erythematosus [32,48-
54]. Surprisingly, only a few of these studies have demon-
strated a functional link between miR-146a expression
and the release of inflammatory mediators or have
attempted to characterise the targets of miR-146a and its
mechanism of action. In addition, despite the early dem-
onstration that miR-146a expression is regulated at the
transcriptional level through NF-κB activation, no
reports have examined whether miR-146a production is
also controlled at the post-transcriptional level
[32,48,49,55,56]. For this reason, we have characterised
the role of miR-146a during IL-1β-induced IL-6 and IL-8
release from primary HASM cells, which are known to
contribute towards chronic inflammation associated with
the development of asthma.
Initial studies demonstrated IL-1β-induced expression
of miR-146a but not miR-155, miR-146b or miR-146*.
Interestingly, a recent report by Kuhn et al [64] that
examined the action of a combination of inflammatory
mediators that included IL-1β, TNF-α and IFN-γ did not
observe an increase in miR-146a expression. Instead, this
study demonstrated down-regulation of multiple miR-
NAs and proceeded to show that reduced miR-25 expres-
sion increased the release of inflammatory mediators,
extracellular matrix turnover and production of contrac-
tile proteins through up-regulation of Krüppel-like factor
4 (KLF4), a target of miR-25 [64].
Examination of the kinetics of miR-146a generation
showed that this increased throughout the 72 h period
following IL-1β stimulation although there appeared to
be differences in the magnitude of the IL-1β-induced
miR-146a expression, which we believe to be the result of
patient-to-patient variation. Interestingly, these observa-
tions differed from previous studies in monocytes/mac-
rophages and alveolar epithelial cells, where there was a
rapid induction of miR-146a expression that peaked at 6-
8 h [32,48,49]. We speculated that this prolonged miR-
146a expression might impact upon other HASM func-
Figure 10 Effect of miR-146a mimics upon IL-1β-induced IL-6 and 
IL-8 mRNA expression. HASM cells were electroporated in the pres-
ence of buffer, control mimic or miR-146a mimic. Cells were then ex-
posed to vehicle control or 1 ng/ml IL-1β and the expression of IL-6 
and IL-8 mRNA was measured by qRT-PCR at 24 h. The results are the 
mean ± SEM of three independent experiments. Panel A shows the ab-
solute increases in IL-6 and IL-8 mRNA whilst the results in panel B are 
expressed as a % compared to IL-1β stimulation (100%).
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tions such as differentiation or contractile potential.
Indeed, studies in C2C12 skeletal muscle cell line have
shown cyclic stretch induced miR-146a expression and
that this promotes proliferation and inhibits differentia-
tion through down-regulation of Numb, an inhibitor of
Notch-induced differentiation [63]. Furthermore, a num-
ber of investigators have implicated changes in miR-146a
expression in metastasis and proliferation associated with
the development of papillary thyroid carcinoma (PTC)
[65-67], cervical cancer [68], ovarian cancer [69], breast
cancer [69-71], pancreatic cancer [70] and prostate can-
cer [70,72].
Having demonstrated IL-1β-induced miR-146a expres-
sion in HASM cells, we next investigated the mechanisms
that regulate the transcription of primary miR-146a and
its subsequent metabolism to produce the mature miR-
146a. Previous studies in HASM cells have shown that
exposure to IL-1β activates NF-κB (via IKK2) [6,16,17]
and the MAP kinase pathways terminating at ERK-1/2,
JNK-1/2 and p38 MAP kinase [6,10,17-21]. Therefore,
established pharmacological inhibitors that had previ-
ously been shown to attenuate IKK2 and MAP kinase
activity in HASM [6,10,17-21] were used to examine the
role of these intracellular pathways. Significantly, these
studies indicated that miR-146a was regulated at both the
transcriptional and post-transcriptional level. As previ-
ously reported [32,48,49,55,56], we showed that initial
transcription of primary miR-146a was mediated through
activation of NF-κB. In addition, we have demonstrated
that ERK-1/2 and JNK-1/2 but not the p38 MAP kinase
pathways regulate the processing of primary miR-146a to
produce mature miR-146a. We attempted to confirm
these pharmacological observations by using siRNA-
mediated knockdown of ERK-1/2 and JNK-1/2 but
observed inhibition of IL-1β-induced miR-146a produc-
tion in the presence of control siRNA. Dicer is thought to
cleave the precursor miRNA to produce the double
stranded miRNA and in combination with TRBP, is
required for the loading of both siRNA and miRNAs into
the Ago2 containing RISC complex. We therefore specu-
late that transfected siRNA might compete with precur-
sor miR-146a for Dicer binding and by this route, siRNA
could block the production of mature miR-146a. Signifi-
cantly, competition between siRNA and miRNA has
recently been demonstrated by Khan A et al. [73]. Over-
all, this is the first report demonstrating a role for ERK-1/
2 and JNK-1/2 pathways in the regulation of miR-146a
biogenesis and although the mechanism is presently
unknown, we speculate that these MAP kinases might
regulate proteins involved in miRNA processing or stabil-
ity.
Examination of the effect of these MAP kinase inhibi-
tors upon generation of inflammatory mediators showed
that IL-6 release was mediated via NF-κB, ERK-1/2 and
p38 MAP kinase whilst IL-8 release was mediated via NF-
κB and ERK-1/2. Significantly, since neither IL-6 nor IL-8
release is influenced by the JNK-1/2 inhibitor, it was pos-
sible to use the JNK-1/2 inhibitor to examine the function
of miR-146a during IL-1β-induced IL-6 and IL-8 release.
Previous investigations in alveolar epithelial cells,
monocytes and macrophages have shown that increased
levels of miR-146a negatively regulate the release of
inflammatory mediators [32,48,49]. Transfection with
miR-146a mimics, which caused a ~3000-fold increase in
cellular miR-146a levels, could also inhibit IL-1β-induced
IL-6 and IL-8 release in HASM cells. However, we
showed that the ~100-fold increase in miR-146a expres-
sion following IL-1β stimulation is insufficient to inhibit
IL-6 and IL-8, since attenuation of miR-146a activity
(using a miR-146a inhibitor) or blocking miR-146a
expression (using the JNK-1/2 inhibitor) had no signifi-
cant effect upon cytokine release. It therefore appears
that other mechanisms negatively regulate the release of
these inflammatory mediators in HASM cells and that
the inhibition in the presence of miR-146a mimic is a
false positive observation resulting from the high cellular
miR-146a levels [74,75].
Since IL-1β has also been shown to induce proliferation
in ASM obtained from guinea-pig and rat trachea, we
also decided to examine whether changes in miR-146a
expression regulated this biological response [11-13].
However, we were unable to show increases in prolifera-
tion or cell number in human ASM following IL-1β expo-
sure whilst miR-146a inhibitors and mimics had no effect
upon the basal proliferation rate.
We next examined whether increases in miR-146a lev-
els following IL-1β stimulation or transfection with miR-
146a mimics could target down-regulation of IRAK-1 or
TRAF6 protein expression as previously reported in
monocytes/macrophages [32,49]. Interestingly, although
we observed a reduction in IRAK-1 and TRAF6 mRNA
expression following IL-1β exposure, this was not
reflected in a reduction in protein levels. In contrast,
miR-146a over-expression following transfection with
miR-146a mimics caused a partial down-regulation in
IRAK-1 and TRAF6 protein expression and a reduction
in IL-6 and IL-8 secretion. However, as with our previous
investigations in IL-1β-stimulated alveolar epithelial cells
[48], the fact that miR-146a mimic failed to inhibit IL-1β-
induced IL-6 and IL-8 mRNA production suggests that
its action is mediated at a stage following IL-6 and IL-8
transcription and not through the down-regulation of
TRAF6 and IRAK1. Although the mechanism of action is
unknown, we speculated that the miR-146a mimic might
down-regulate protein(s) involved in one or more steps
including IL-6 and IL-8 translation and/or secretion.Larner-Svensson et al. Respiratory Research 2010, 11:68
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Conclusion
We have shown that IL-1β-induced a time- and concen-
tration-dependent increase in miR-146a expression. As
with miR-155 and the regulation of the immune response
[30], we demonstrate that the function of miR-146a
expression is cell-type specific. Thus, unlike alveolar epi-
thelial cells and monocytes/macrophages, increased miR-
146a expression following activation of the innate
immune response does not appear to negatively regulate
t h e  r e l eas e  o f  i n fl a m m a t o ry  m ed i a t o r s  i n  HAS M  c e l l s.
This may reflect the fact that the increases in miR-146a
expression were insufficient to down-regulate the expres-
sion of IRAK-1, TRAF6 or other proteins that are
involved in regulating the release of inflammatory media-
tors [32,48,49]. We have also shown that unlike ASM
derived from guinea-pigs and rats, IL-1β does not induce
proliferation in HASM and that IL-1β-induced miR-146a
expression does not regulate basal proliferation in
HASM. Interestingly, this study also demonstrates that
the processing of primary miR-146a is regulated by the
MAP kinases, ERK-1/2 and JNK-1/2. Given that activa-
tion of these MAP kinases has been demonstrated in a
host of biological responses, it will be interesting to deter-
mine the mechanism by which MAP kinases regulate the
biogenesis of miR-146a and other miRNAs.
Additional material
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
HML performed all the cell based studies and drafted the manuscript; ET and
XJ measured the levels of primary miR-146a, AEW and MMP participated in the
conception and design of the study: KFC and MAL participated in the concep-
tion and design of the study and were involved in drafting the manuscript. All
authors have read and approved the final manuscript.
Acknowledgements
We would like to thanks Prof. David Baltimore and Dr Mark Boldin of the Califor-
nia Institute of Technology, San Diego USA for providing RT-PCR primers for 
measurement of primary miR-146a. This work was supported by the National 
Heart and Lung Institute PhD Studentship (HML), Wellcome Trust (076111 to 
MAL and AEW; 085935 to KFC), Asthma UK (07/015 to MMP), NIHR Translational 
Research Facility Grant (ET), NIHR Royal Brompton Respiratory Biomedical 
Research Unit (KFC) and Chinese Overseas Study Scholarship (XJ).
Author Details
1Airway Disease, National Heart and Lung Institute, Imperial College London 
SW3 6LY, UK and 2NIHR Translational Research Facility in Respiratory Medicine, 
University of Manchester, Education and Research Centre, Wythenshawe 
Hospital, Southmoor Road, Manchester M23 9LY, UK
References
1. Holgate ST, Price D, Valovirta E: Asthma out of control? A structured 
review of recent patient surveys.  BMC Pulm Med 2006, 6(Suppl 1):S2.
2. Holgate ST, Polosa R: The mechanisms, diagnosis, and management of 
severe asthma in adults.  Lancet 2006, 368:780-793.
3. Barnes PJ: Immunology of asthma and chronic obstructive pulmonary 
disease.  Nat Rev Immunol 2008, 8:183-192.
4. Holgate ST: Pathogenesis of asthma.  Clin Exp Allergy 2008, 38:872-897.
5. Issa R, Xie S, Lee KY, Stanbridge RD, Bhavsar P, Sukkar MB, Chung KF: GRO-
alpha regulation in airway smooth muscle by IL-1beta and TNF-alpha: 
role of NF-kappaB and MAP kinases.  Am J Physiol Lung Cell Mol Physiol 
2006, 291:L66-L74.
6. Wuyts WA, Vanaudenaerde BM, Dupont LJ, Demedts MG, Verleden GM: 
Involvement of p38 MAPK, JNK, p42/p44 ERK and NF-kappaB in IL-
1beta-induced chemokine release in human airway smooth muscle 
cells.  Respir Med 2003, 97:811-817.
7. Issa R, Sorrentino R, Sukkar MB, Sriskandan S, Chung KF, Mitchell JA: 
Differential regulation of CCL-11/eotaxin-1 and CXCL-8/IL-8 by gram-
positive and gram-negative bacteria in human airway smooth muscle 
cells.  Respir Res 2008, 9:30.
8. Xie S, Issa R, Sukkar MB, Oltmanns U, Bhavsar PK, Papi A, Caramori G, 
Adcock I, Chung KF: Induction and regulation of matrix 
metalloproteinase-12 in human airway smooth muscle cells.  Respir Res 
2005, 6:148.
9. Pascual RM, Carr EM, Seeds MC, Guo M, Panettieri RA, Peters SP, Penn RB: 
Regulatory features of interleukin-1beta-mediated prostaglandin E2 
synthesis in airway smooth muscle.  Am J Physiol Lung Cell Mol Physiol 
2006, 290:L501-L508.
10. Oltmanns U, Issa R, Sukkar MB, John M, Chung KF: Role of c-jun N-
terminal kinase in the induced release of GM-CSF, RANTES and IL-8 
from human airway smooth muscle cells.  Br J Pharmacol 2003, 
139:1228-1234.
11. De S, Zelazny ET, Souhrada JF, Souhrada M: IL-1 beta and IL-6 induce 
hyperplasia and hypertrophy of cultured guinea pig airway smooth 
muscle cells.  J Appl Physiol 1995, 78:1555-1563.
12. De S, Zelazny ET, Souhrada JF, Souhrada M: Interleukin-1 beta stimulates 
the proliferation of cultured airway smooth muscle cells via platelet-
derived growth factor.  Am J Respir Cell Mol Biol 1993, 9:645-651.
13. Zhai W, Eynott PR, Oltmanns U, Leung SY, Chung KF: Mitogen-activated 
protein kinase signalling pathways in IL-1 beta-dependent rat airway 
smooth muscle proliferation.  Br J Pharmacol 2004, 143:1042-1049.
14. O'Neill LA: When signaling pathways collide: positive and negative 
regulation of toll-like receptor signal transduction.  Immunity 2008, 
29:12-20.
15. Dinarello CA: Immunological and inflammatory functions of the 
interleukin-1 family.  Annu Rev Immunol 2009, 27:519-550.
16. Birrell MA, Hardaker E, Wong S, McCluskie K, Catley M, De Alba J, Newton 
R, Haj-Yahia S, Pun KT, Watts CJ, et al.: Ikappa-B kinase-2 inhibitor blocks 
inflammation in human airway smooth muscle and a rat model of 
asthma.  Am J Respir Crit Care Med 2005, 172:962-971.
17. Wang CC, Lin WN, Lee CW, Lin CC, Luo SF, Wang JS, Yang CM: 
Involvement of p42/p44 MAPK, p38 MAPK, JNK, and NF-kappaB in IL-
1beta-induced VCAM-1 expression in human tracheal smooth muscle 
cells.  Am J Physiol Lung Cell Mol Physiol 2005, 288:L227-L237.
18. Laporte JD, Moore PE, Lahiri T, Schwartzman IN, Panettieri RA, Shore SA: 
p38 MAP kinase regulates IL-1 beta responses in cultured airway 
smooth muscle cells.  Am J Physiol Lung Cell Mol Physiol 2000, 
279:L932-L941.
19. Laporte JD, Moore PE, Abraham JH, Maksym GN, Fabry B, Panettieri RA, 
Shore SA: Role of ERK MAP kinases in responses of cultured human 
airway smooth muscle cells to IL-1beta.  Am J Physiol 1999, 
277:L943-L951.
20. Hedges JC, Singer CA, Gerthoffer WT: Mitogen-activated protein kinases 
regulate cytokine gene expression in human airway myocytes.  Am J 
Respir Cell Mol Biol 2000, 23:86-94.
21. Hallsworth MP, Moir LM, Lai D, Hirst SJ: Inhibitors of mitogen-activated 
protein kinases differentially regulate eosinophil-activating cytokine 
release from human airway smooth muscle.  Am J Respir Crit Care Med 
2001, 164:688-697.
22. Bartel DP: MicroRNAs: target recognition and regulatory functions.  Cell 
2009, 136:215-233.
23. Filipowicz W, Jaskiewicz L, Kolb FA, Pillai RS: Post-transcriptional gene 
silencing by siRNAs and miRNAs.  Curr Opin Struct Biol 2005, 15:331-341.
Additional file 1 Effect of inhibitors of IKK2 and MAP kinases upon 
HASM cell viability. HASM cells were pre-treated for 60 min with the indi-
cated concentrations of the inhibitors of IKK-2 (TPCA-1), MEK-1/2 
(PD098059), JNK-1/2 (SP600125) and p38 MAP kinase (SB203580). Following 
exposure to IL-1β (1 ng/ml) for 24 h, cell viability was measured using an 
MTT assay. Results are expressed as the % of non-treated cells and are the 
mean ± SEM of 3 independent experiments.
Received: 14 January 2010 Accepted: 2 June 2010 
Published: 2 June 2010
This article is available from: http://respiratory-research.com/content/11/1/68 © 2010 Larner-Svensson et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Respiratory Research 2010, 11:68Larner-Svensson et al. Respiratory Research 2010, 11:68
http://respiratory-research.com/content/11/1/68
Page 12 of 13
24. Winter J, Jung S, Keller S, Gregory RI, Diederichs S: Many roads to 
maturity: microRNA biogenesis pathways and their regulation.  Nat Cell 
Biol 2009, 11:228-234.
25. Kim VN, Han J, Siomi MC: Biogenesis of small RNAs in animals.  Nat Rev 
Mol Cell Biol 2009, 10:126-139.
26. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB: Prediction of 
mammalian microRNA targets.  Cell 2003, 115:787-798.
27. Doench JG, Sharp PA: Specificity of microRNA target selection in 
translational repression.  Genes Dev 2004, 18:504-511.
28. Didiano D, Hobert O: Perfect seed pairing is not a generally reliable 
predictor for miRNA-target interactions.  Nat Struct Mol Biol 2006, 
13:849-851.
29. Lindsay MA: microRNAs and the immune response.  Trends Immunol 
2008, 29:343-351.
30. Tsitsiou E, Lindsay MA: microRNAs and the immune response.  Curr Opin 
Pharmacol 2009, 9:514-520.
31. Taganov KD, Boldin MP, Baltimore D: MicroRNAs and immunity: tiny 
players in a big field.  Immunity 2007, 26:133-137.
32. Taganov KD, Boldin MP, Chang KJ, Baltimore D: NF-kappaB-dependent 
induction of microRNA miR-146, an inhibitor targeted to signaling 
proteins of innate immune responses.  Proc Natl Acad Sci USA 2006, 
103:12481-12486.
33. O'connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D: MicroRNA-
155 is induced during the macrophage inflammatory response.  Proc 
Natl Acad Sci USA 2007, 104:1604-1609.
34. Tili E, Michaille JJ, Cimino A, Costinean S, Dumitru CD, Adair B, Fabbri M, 
Alder H, Liu CG, Calin GA, et al.: Modulation of miR-155 and miR-125b 
Levels following Lipopolysaccharide/TNF-{alpha} Stimulation and 
Their Possible Roles in Regulating the Response to Endotoxin Shock.  J 
Immunol 2007, 179:5082-5089.
35. Ceppi M, Pereira PM, Dunand-Sauthier I, Barras E, Reith W, Santos MA, 
Pierre P: MicroRNA-155 modulates the interleukin-1 signaling pathway 
in activated human monocyte-derived dendritic cells.  Proc Natl Acad 
Sci USA 2009, 106:2735-2740.
36. Moschos SA, Williams AE, Perry MM, Birrell MA, Belvisi MG, Lindsay MA: 
Expression profiling in vivo demonstrates rapid changes in lung 
microRNA levels following lipopolysaccharide-induced inflammation 
but not in the anti-inflammatory action of glucocorticoids.  BMC 
Genomics 2007, 8:240.
37. Bazzoni F, Rossato M, Fabbri M, Gaudiosi D, Mirolo M, Mori L, Tamassia N, 
Mantovani A, Cassatella MA, Locati M: Induction and regulatory function 
of miR-9 in human monocytes and neutrophils exposed to 
proinflammatory signals.  Proc Natl Acad Sci USA 2009, 106:5282-5287.
38. Thai TH, Calado DP, Casola S, Ansel KM, Xiao C, Xue Y, Murphy A, 
Frendewey D, Valenzuela D, Kutok JL, et al.: Regulation of the germinal 
center response by microRNA-155.  Science 2007, 316:604-608.
39. Ruggiero T, Trabucchi M, De SF, Zupo S, Harfe BD, McManus MT, 
Rosenfeld MG, Briata P, Gherzi R: LPS induces KH-type splicing 
regulatory protein-dependent processing of microRNA-155 precursors 
in macrophages.  FASEB J 2009, 23:2898-2908.
40. O'connell RM, Rao DS, Chaudhuri AA, Boldin MP, Taganov KD, Nicoll J, 
Paquette RL, Baltimore D: Sustained expression of microRNA-155 in 
hematopoietic stem cells causes a myeloproliferative disorder.  J Exp 
Med 2008, 205:585-594.
41. O'connell RM, Chaudhuri AA, Rao DS, Baltimore D: Inositol phosphatase 
SHIP1 is a primary target of miR-155.  Proc Natl Acad Sci USA 2009, 
106:7113-7118.
42. Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR, van 
Dongen S, Grocock RJ, Das PP, Miska EA, et al.: Requirement of bic/
microRNA-155 for normal immune function.  Science 2007, 316:608-611.
43. Lu LF, Thai TH, Calado DP, Chaudhry A, Kubo M, Tanaka K, Loeb GB, Lee H, 
Yoshimura A, Rajewsky K, et al.: Foxp3-dependent microRNA155 confers 
competitive fitness to regulatory T cells by targeting SOCS1 protein.  
Immunity 2009, 30:80-91.
44. Kohlhaas S, Garden OA, Scudamore C, Turner M, Okkenhaug K, Vigorito E: 
Cutting Edge: The Foxp3 Target miR-155 Contributes to the 
Development of Regulatory T Cells.  J Immunol 2009, 182:2578-2582.
45. Vigorito E, Perks KL, Abreu-Goodger C, Bunting S, Xiang Z, Kohlhaas S, Das 
PP, Miska EA, Rodriguez A, Bradley A, et al.: microRNA-155 regulates the 
generation of immunoglobulin class-switched plasma cells.  Immunity 
2007, 27:847-859.
46. Dorsett Y, McBride KM, Jankovic M, Gazumyan A, Thai TH, Robbiani DF, Di 
Virgilio M, San Martin BR, Heidkamp G, Schwickert TA, et al.: MicroRNA-
155 suppresses activation-induced cytidine deaminase-mediated 
Myc-Igh translocation.  Immunity 2008, 28:630-638.
47. Teng G, Hakimpour P, Landgraf P, Rice A, Tuschl T, Casellas R, Papavasiliou 
FN: MicroRNA-155 is a negative regulator of activation-induced 
cytidine deaminase.  Immunity 2008, 28:621-629.
48. Perry MM, Moschos SA, Williams AE, Shepherd NJ, Larner-Svensson HM, 
Lindsay MA: Rapid Changes in MicroRNA-146a Expression Negatively 
Regulate the IL-1{beta}-Induced Inflammatory Response in Human 
Lung Alveolar Epithelial Cells.  J Immunol 2008, 180:5689-5698.
49. Hou J, Wang P, Lin L, Liu X, Ma F, An H, Wang Z, Cao X: MicroRNA-146a 
feedback inhibits RIG-I-dependent Type I IFN production in 
macrophages by targeting TRAF6, IRAK1, and IRAK2.  J Immunol 2009, 
183:2150-2158.
50. Liu X, Nelson A, Wang X, Kanaji N, Kim M, Sato T, Nakanishi M, Li Y, Sun J, 
Michalski J, et al.: MicroRNA-146a modulates human bronchial epithelial 
cell survival in response to the cytokine-induced apoptosis.  Biochem 
Biophys Res Commun 2009, 380:177-182.
51. Yamasaki K, Nakasa T, Miyaki S, Ishikawa M, Deie M, Adachi N, Yasunaga Y, 
Asahara H, Ochi M: Expression of MicroRNA-146a in osteoarthritis 
cartilage.  Arthritis Rheum 2009, 60:1035-1041.
52. Stanczyk J, Pedrioli DM, Brentano F, Sanchez-Pernaute O, Kolling C, Gay 
RE, Detmar M, Gay S, Kyburz D: Altered expression of MicroRNA in 
synovial fibroblasts and synovial tissue in rheumatoid arthritis.  Arthritis 
Rheum 2008, 58:1001-1009.
53. Jones SW, Watkins G, Le GN, Roberts S, Murphy CL, Brockbank SM, 
Needham MR, Read SJ, Newham P: The identification of differentially 
expressed microRNA in osteoarthritic tissue that modulate the 
production of TNF-alpha and MMP13.  Osteoarthritis Cartilage 2009, 
17:464-472.
54. Tang Y, Luo X, Cui H, Ni X, Yuan M, Guo Y, Huang X, Zhou H, de Vries N, Tak 
PP, et al.: MicroRNA-146A contributes to abnormal activation of the 
type i interferon pathway in human lupus by targeting the key 
signaling proteins.  Arthritis Rheum 2009, 60:1065-1075.
55. Motsch N, Pfuhl T, Mrazek J, Barth S, Grasser FA: Epstein-Barr virus-
encoded latent membrane protein 1 (LMP1) induces the expression of 
the cellular microRNA miR-146a.  RNA Biol 2007, 4:131-137.
56. Pichler K, Schneider G, Grassmann R: MicroRNA miR-146a and further 
oncogenesis-related cellular microRNAs are dysregulated in HTLV-1-
transformed lymphocytes.  Retrovirology 2008, 5:100.
57. Davis BN, Hilyard AC, Lagna G, Hata A: SMAD proteins control DROSHA-
mediated microRNA maturation.  Nature 2008, 454:56-61.
58. Trabucchi M, Briata P, Garcia-Mayoral M, Haase AD, Filipowicz W, Ramos A, 
Gherzi R, Rosenfeld MG: The RNA-binding protein KSRP promotes the 
biogenesis of a subset of microRNAs.  Nature 2009, 459:1010-1014.
59. De Souza PM, Kankaanranta H, Michael A, Barnes PJ, Giembycz MA, 
Lindsay MA: Caspase-catalyzed cleavage and activation of Mst1 
correlates with eosinophil but not neutrophil apoptosis.  Blood 2002, 
99:3432-3438.
60. Hacker H, Redecke V, Blagoev B, Kratchmarova I, Hsu LC, Wang GG, Kamps 
MP, Raz E, Wagner H, Hacker G, et al.: Specificity in Toll-like receptor 
signalling through distinct effector functions of TRAF3 and TRAF6.  
Nature 2006, 439:204-207.
61. Takaesu G, Ninomiya-Tsuji J, Kishida S, Li X, Stark GR, Matsumoto K: 
Interleukin-1 (IL-1) receptor-associated kinase leads to activation of 
TAK1 by inducing TAB2 translocation in the IL-1 signaling pathway.  
Mol Cell Biol 2001, 21:2475-2484.
62. Williams AE, Perry MM, Moschos SA, Larner-Svensson HM, Lindsay MA: 
Role of miRNA-146a in the regulation of the innate immune response 
and cancer.  Biochem Soc Trans 2008, 36:1211-1215.
63. Kuang W, Tan J, Duan Y, Duan J, Wang W, Jin F, Jin Z, Yuan X, Liu Y: Cyclic 
stretch induced miR-146a upregulation delays C2C12 myogenic 
differentiation through inhibition of Numb.  Biochem Biophys Res 
Commun 2009, 378:259-263.
64. Kuhn AR, Schlauch K, Lao R, Halayko AJ, Gerthoffer WT, Singer CA: 
MicroRNA Expression in Human Airway Smooth Muscle Cells: Role of 
miR-25 in Regulation of Airway Smooth Muscle Phenotype.  Am J Respir 
Cell Mol Biol 2010, 42:506-513.
65. He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, Calin GA, Liu 
CG, Franssila K, Suster S, et al.: The role of microRNA genes in papillary 
thyroid carcinoma.  Proc Natl Acad Sci USA 2005, 102:19075-19080.Larner-Svensson et al. Respiratory Research 2010, 11:68
http://respiratory-research.com/content/11/1/68
Page 13 of 13
66. Pallante P, Visone R, Ferracin M, Ferraro A, Berlingieri MT, Troncone G, 
Chiappetta G, Liu CG, Santoro M, Negrini M, et al.: MicroRNA deregulation 
in human thyroid papillary carcinomas.  Endocr Relat Cancer 2006, 
13:497-508.
67. Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR, de la CA: 
Common SNP in pre-miR-146a decreases mature miR expression and 
predisposes to papillary thyroid carcinoma.  Proc Natl Acad Sci USA 2008, 
105:7269-7274.
68. Wang X, Tang S, Le SY, Lu R, Rader JS, Meyers C, Zheng ZM: Aberrant 
expression of oncogenic and tumor-suppressive microRNAs in cervical 
cancer is required for cancer cell growth.  PLoS ONE 2008, 3:e2557.
69. Shen J, Ambrosone CB, Dicioccio R, Odunsi K, Lele SB, Zhao H: A 
Functional Polymorphism in the miR-146a Gene and Age of Familial 
Breast/Ovarian Cancer Diagnosis.  Carcinogenesis 2008, 29:1963-1966.
70. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio 
M, Roldo C, Ferracin M, et al.: A microRNA expression signature of human 
solid tumors defines cancer gene targets.  Proc Natl Acad Sci USA 2006, 
103:2257-2261.
71. Hu Z, Liang J, Wang Z, Tian T, Zhou X, Chen J, Miao R, Wang Y, Wang X, 
Shen H: Common genetic variants in pre-microRNAs were associated 
with increased risk of breast cancer in Chinese women.  Hum Mutat 
2008, 30:79-84.
72. Lin SL, Chiang A, Chang D, Ying SY: Loss of mir-146a function in 
hormone-refractory prostate cancer.  RNA 2008, 14:417-424.
73. Khan AA, Betel D, Miller ML, Sander C, Leslie CS, Marks DS: Transfection of 
small RNAs globally perturbs gene regulation by endogenous 
microRNAs.  Nat Biotechnol 2009, 27:549-555.
74. Liew FY, Xu D, Brint EK, O'Neill LA: Negative regulation of toll-like 
receptor-mediated immune responses.  Nat Rev Immunol 2005, 
5:446-458.
75. O'Neill LA: 'Fine tuning' TLR signaling.  Nat Immunol 2008, 9:459-461.
doi: 10.1186/1465-9921-11-68
Cite this article as: Larner-Svensson et al., Pharmacological studies of the 
mechanism and function of interleukin-1?-induced miRNA-146a expression 
in primary human airway smooth muscle Respiratory Research 2010, 11:68